{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:04:14Z","timestamp":1772039054552,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the outcomes of delay in care secondary to the coronavirus pandemic in patients requiring intravitreal anti\u2013vascular endothelial growth factor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective review was performed, and subjects were divided into two groups: 1) a study group of patients who experienced a treatment delay of \u22656 weeks from the intended follow-up during the coronavirus pandemic and resumed treatment with \u22652 anti\u2013vascular endothelial growth factor injections over 6 months following treatment delay, and 2) a control group of patients who received regular care throughout the coronavirus pandemic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Totally, 234 subjects were analyzed. The mean treatment delay from the intended follow-up in the study group was 11.8 (\u00b14.0) weeks. Visual acuity and central macular thickness worsened from baseline to 6 months after resuming anti\u2013vascular endothelial growth factor therapy in the study group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001 and <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001, respectively). Visual acuity and central macular thickness were better in the control group compared with the study group at the end of the 6-month study period (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001 for both).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Treatment delay in subjects undergoing anti\u2013vascular endothelial growth factor therapy for retina disease during the coronavirus pandemic had worse visual and anatomical outcomes despite reinitiating treatment over 6 months compared with a control group, suggesting irreversibility and permanence of outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003276","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:30:27Z","timestamp":1628548227000},"page":"2456-2461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMIC"],"prefix":"10.1097","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-6155","authenticated-orcid":false,"given":"Ryan B.","family":"Rush","sequence":"first","affiliation":[{"name":"Panhandle Eye Group, Amarillo, Texas;"},{"name":"Texas Tech University Health Science Center, Amarillo, Texas; and"},{"name":"Southwest Retina Specialists, Amarillo, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sloan W.","family":"Rush","sequence":"additional","affiliation":[{"name":"Panhandle Eye Group, Amarillo, Texas;"},{"name":"Texas Tech University Health Science Center, Amarillo, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40123-020-00251-z","article-title":"Protect healthcare workers and patients from COVID-19: the experience of two tertiary ophthalmology care referral centers in Italy","volume":"9","author":"Parravano","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41433-020-0880-6","article-title":"Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy","volume":"34","author":"Borrelli","year":"2020","journal-title":"Eye (Lond)"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.oret.2020.05.015","article-title":"Management of neovascular age-related macular degeneration during the COVID-19 pandemia","volume":"4","author":"Corradetti","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41433-020-0925-x","article-title":"Current safety preferences for intravitreal injection during COVID-19 pandemic","volume":"34","author":"Shmueli","year":"2020","journal-title":"Eye (Lond)"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s00417-020-04858-7","article-title":"Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let's be ready for a plausible \u201crebound effect\u201d","volume":"258","author":"Borrelli","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00417-020-04955-7","article-title":"Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic","volume":"258","author":"Borrelli","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-20250607","first-page":"S2468","article-title":"The effect of delay in care among patients requiring intravitreal injections","author":"Song","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","article-title":"The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration","volume":"64","author":"Talks","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor","volume":"4","author":"Soares","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3928\/23258160-20190301-05","article-title":"Loss to follow-up in patients with retinal vein occlusion undergoing intravitreal anti-VEGF injections","volume":"50","author":"Gao","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:05:42Z","timestamp":1749319542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003276","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}